Physicians' Academy for Cardiovascular Education

Beyond statins: The role of ezetimibe in targeting residual risk

10' education - Aug. 29, 2016 - ESC 2016, Rome - Chris Packard, MD – University of Glasgow, United Kingdom

This lecture was part of a CME accredited symposium: How to address residual risk post ACS: LDL-c, dyslipidemia, and inflammation held at ESC 2016 in Rome

Video navigation menu

  • Impact of dual inhibition of cholesterol synthesis and absorption 01:27
  • IMPROVE-IT: results of ezetimibe on top of statin 02:47
  • Clinical evidence for LDL lowering supported by genetic studies 03:56
  • Long-term benefits of LDL-lowering: WOSCOPS 20-year follow-up 06:07
  • Options for optimal LDL/non HDL-C lowering 10:53
  • Summary 11:30

Educational information

The educational objectives of this symposum were to:


Professor Chris Packard, MD: R&D Director, NHS Greater Glasgow & Clyde Health Board, Honorary Professor of Vascular Biochemistry, University of Glasgow - Consultant Clinical Scientist, Dept of Biochemistry NHS Greater Glasgow & Clyde Health Board


This EBAC accredited symposium was funded by unrestricted educational grants received from Novartis, MSD, Amgen

View slides of this lecture

The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: